DUET-01: A first-in-human, phase 1/2 study of BOXR1030 in patients with advanced glypican-3-positive solid tumors. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...
Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30 patients with advanced disease. The pharma giant halted the phase 1 trial of QEQ278 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results